Perspective Therapeutics (NYSEAMERICAN:CATX) Hits New 1-Year High at $1.62

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) reached a new 52-week high during trading on Tuesday . The stock traded as high as 1.62 and last traded at 1.60, with a volume of 1449231 shares. The stock had previously closed at 1.53.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $1.50 price objective (up previously from $1.20) on shares of Perspective Therapeutics in a research note on Monday, April 1st. B. Riley boosted their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a “buy” rating in a research note on Tuesday, April 9th.

Perspective Therapeutics Stock Down 0.6 %

The firm has a market capitalization of $991.89 million, a P/E ratio of -16.90 and a beta of 1.56. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07.

Insider Transactions at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at this link. Company insiders own 5.72% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Simplicity Wealth LLC purchased a new position in Perspective Therapeutics during the 1st quarter valued at about $40,000. Bank of New York Mellon Corp bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $42,000. Taylor & Morgan Wealth Management LLC boosted its position in Perspective Therapeutics by 8.7% during the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after acquiring an additional 50,000 shares in the last quarter. HighTower Advisors LLC bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $314,000. Finally, Perkins Capital Management Inc. bought a new stake in Perspective Therapeutics during the 3rd quarter valued at approximately $731,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.